From the CEO

Once again, watch Stan Erck interviewed on CNBC's Mad Money with Jim Cramer 02/13/15

Watch Stan Erck interviewed on CNBC's Mad Money with Jim Cramer 01/15/15

Watch BioWorld interview with Stan Erck 10/31/14

Listen to BioTech Nation Radio Interview with Stan Erck 10/29/14

Watch coverage of Novavax Ebola Program from ABC News Channel 7 WJLA 10/28/2014

Watch Stan Erck's Interview on CNBC discussing the new Ebola Program 10/27/2014

Watch Stan Erck's Interview on The Street 09/23/2014

At Novavax, we’ve brought together state-of-the-art science, cutting-edge manufacturing techniques, and passionate, talented professionals to create the vaccines of tomorrow. In light of today’s critical health concerns, we aim to provide real solutions through rapid vaccine production worldwide. We believe that halting the spread of contagious diseases is possible through innovation and perseverance.

— Stanley C. Erck, President & CEO

About Novavax

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Product Pipeline

Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). We also have additional pre-clinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS).

Corporate Overview

Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.